Neurogene Inc (NGNE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $482.33M
Last updated: Nov 17, 2026 at 4:10 PM ET
Neurogene Inc (NGNE) Statistics
Neurogene (NGNE) has a market cap of $482.33M and an enterprise value of $403.39M. Its share count is up 30.83% from a year earlier. It holds $78.94M more cash than debt, 16.37% of its market cap.
Total Valuation
Enterprise value is 16.37% below the market cap, as cash exceeds debt.
| Market Cap | $482.33M |
|---|---|
| Enterprise Value | $403.39M |
| Latest price (Nov 17, 2026) | $23.10 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 1.45% over 52 weeks and trades 16.33% below its 50-day average.
| Beta (1Y) | 1.44 |
|---|---|
| 52-Week Change | +1.45% |
| 1-Month Change | -4.43% |
| 3-Month Change | -41.42% |
| 6-Month Change | -14.06% |
| 5-Year Change | -81.21% |
| 10-Year Change | -86.84% |
| Total Return (1Y) | +1.45% |
| Total Return (3Y CAGR) | +19.90% |
| Total Return (5Y CAGR) | -26.75% |
| Return vs SPY (1Y) | -3.41% |
| Max Drawdown (1Y) | -49.67% |
| Max Drawdown (3Y) | -89.74% |
| Sharpe Ratio (1Y) | 0.11 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $27.61 |
| 200-Day Average | $28.22 |
| 52-Week Range | $15.93 to $43.66 |
| RSI (14 Days) | 38.5 |
| Average Volume (20 Days) | 297.67K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 19.97x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 19.97x |
|---|---|
| Quick Ratio | 19.97x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -28.54% over the last 12 months, against a 5-year average of -30.39%.
| Return on Equity (ROE) | -33.59% |
|---|---|
| Return on Assets (ROA) | -31.54% |
| Return on Invested Capital (ROIC) | -28.54% |
| ROA (5Y Average) | -31.54% |
| ROIC (5Y Average) | -30.39% |
Scores
NGNE has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$787.00K |
| Operating Income | -$129.93M |
| Pretax Income | -$117.96M |
| Net Income | -$119.18M |
| Reported EPS (TTM) | -$5.10 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 93.88% of the $377.90M in total assets.
| Cash and Equivalents | $78.94M |
|---|---|
| Total Debt | $2.00K |
| Net Cash | $78.94M |
| Net Cash Per Share | $2.85 |
| Working Capital | $344.58M |
| Shareholder Equity | $354.79M |
| Book Value Per Share | $12.81 |
| Total Assets | $377.90M |
| Total Liabilities | $23.11M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.08M of capital spending, operating cash flow left -$97.53M of free cash flow.
| Operating Cash Flow | -$96.45M |
|---|---|
| Capital Expenditures | $1.08M |
| Free Cash Flow | -$97.53M |
| FCF Per Share | -$4.87 |
| Depreciation and Amortization | $6.64M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +8.57% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +8.57% |
Dividends and Yields
NGNE does not pay a dividend. Its free cash flow yield is -15.24%.
| FCF Yield | -15.24% |
|---|---|
| Buyback Yield | -2.29% |
| Shareholder Yield | -2.29% |
Stock Splits
The last split was a 1-for-4 reverse split on Dec 19, 2023.
| Last Split Date | Dec 19, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:4 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NGNE
What is NGNE's market cap?
Neurogene has a market cap of $482.33M. Its enterprise value, which adds debt and subtracts cash, is $403.39M.
How many shares of NGNE are outstanding?
Neurogene has 27.70M shares outstanding. The count is up 30.83% from a year earlier.
Does NGNE pay a dividend?
No. Neurogene does not pay a dividend.
How much debt does NGNE have?
Neurogene has $2.00K of total debt and $78.94M of cash and equivalents, a net cash position of $78.94M.
NGNE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors